For a long time, eosinophils were regarded as the central effector cells of asthma and were interpreted in the classical model as a direct damaging agent of the epithelium, as an amplifier of bronchial hyperresponsiveness and as the main driver of type 2-mediated airway inflammation. Scientific developments over the past two decades have differentiated, expanded and in some cases questioned this picture. Are eosinophils in fact primary culprits – or merely markers of more complex immunological patterns? A new Lancet publication sheds some light on this.
Autoren
- Tanja Schliebe
Publikation
- Asthma/COPD-Special
Related Topics
You May Also Like
- Study report: TBS v3 and v4 in comparison
Analysis of OsteoLaus study data
- Atopic dermatitis: proven therapeutic principles and innovations
From healthcare research to precision medicine
- SGLT2 inhibitors and glucocorticoids
Protective effect on kidney function is maintained
- Study report: Nicotinamide for skin cancer prevention
Cohort study analyzed data from over 30,000 patients
- Psychooncology
Communication as the key to therapy adherence
- How do weight loss interventions affect the muscles?
Reflective evaluation: do not neglect qualitative aspects
- From biomarkers to gene therapies
Getting to know ataxias
- Evidence-based therapy for psoriasis in difficult locations